Hememics Biotechnologies, a Gaithersburg, MD-based developer of a handheld, multiplexed biosensor platform, raised $2M in Seed 2 funding.
The round saw participation from existing investors and Maryland Technology Development Corporation (TEDCO).
The company intends to use the funds to accelerate its growth and gain early commercial success.
Led by CEO John Warden, Jr., and Co-founder, President and CSO, Dr. David Ho, Hememics uses graphene-based sensors with its patented bio preservatives to bring handheld, lab-quality testing performance to wherever needed – whether it is a farm, emergency room or battlefield. Its rugged platform consists of a portable reader utilizing a single-use biochip with 32 sensors which can be individually programmed to detect molecular, antigen and antibody targets.
